• Publications:
• Essai randomisé contrôlé comparant l’association pembrolizumab plus chimiothérapie à la chimiothérapie seule dans le mésothéliome pleural avancé, non prétraité (essai IND. 227, IFCT-1901)
• IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
• Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
• Synopsis: IFCT-1901_synopsis_V4_20210916_IFCT.pdf